We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in...
We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in...
In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid...
In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid...
In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid...
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
View the full ON-Demand Video now! This live, virtual, interactive patient education event included presentations and panel discussions covering...
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.
En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras.
Thank you for joining us on Saturday for the 2023 Targeted Therapies in Lung Cancer Patient Forum!
The full unedited versions of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage and Second Stage, are now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks.
Apply Online Now for this paid opportunity to tell your story!
Apply Online Now for this paid opportunity to tell your story!
GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview
In 2020 I had left lower lobectomy for a single nodule 17 mm x11 mm with diagnosis of Invasive mucinous adenocarcinoma. No lymph or pleural involvement but STAS was present according to pathology report. Subsequent scans have shown a very small nodule in upper left lobe which is “slightly more conspicuous”. My surgeon has ordered Ct with contrast for my next scan in December. I had a repeat VATS two weeks after the first surgery due to a rather large hemothorax 1.8 liters and had a transfusion.
If you want to keep up on what content GRACE is producing, or if there is a specific program you are interested in seeing throughout the years, there are many ways to find that information. One of the best tools is the navigation drop-down under EDUCATE.
Is Palliative Care Right for You?
Submitted by JanineT Forum Moderator on Mon, 07/22/2019 - 12:36
From the Grace Archives | Originally published March 28, 2011 | By Dr Ramchandran | 5 Comments
We are proud to present this series on Clinical Trials Experiences.
This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey.
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock